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Two proteolytic activities that degrade [Leu’lenkephalin were found in Torpedo californica electric organ. 
One is a soluble aminopeptidase that degrades enkephalin at the Tyr’-Gly’ peptide bond, and the second 
is an endopeptidase that degrades enkephalin at the Gly3-Phe* peptide bond. The aminopeptidase is 
inhibited by low concentrations of puromycin and bestatin. More than 60% of the endopeptidase is 
associated with the particulate fraction and is almost completely inhibited by low concentrations of 
captopril (SQ 14225) or SQ 20881 (potent inhibitors of angiotensin converting enzyme). Thiorphan and 
phoshoramidon (potent enkephalinase inhibitors) are much less effective. The pattern of cleavage and 
inhibition of the particulate endopeptidase thus resembles that of angiotensin converting enzyme. 
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1. INTRODUCTION 
Proteases in the nervous system are implicated in 
the regulation of membrane receptors [l], in 
modulation of synaptic transmission at the 
neuromuscular junction [2] and in the metabolism 
of peptidergic signals [3,4]. This last group is of 
special interest since many peptides are currently 
implicated in modulation of neuronal activity. One 
such modulatory neuropeptide is enkephalin, a 
naturally occurring opioid pentapeptide, which has 
a variety of biological functions in the central and 
peripheral nervous system (reviews [5-71). 
Enkephalins affect neuronal transmission at the 
neuromuscular junction [8], and it has been shown 
that opiates modulate synaptic efficacy in the elec- 
tric organ of Torpedo (D.M. Michaelson et al. in 
preparation) a tissue of embryonic muscle origin 
PI - 
available on proteases which are capable of 
degrading enkephalin at the neuromuscular junc- 
tion or in the fish electric organ. We report here 
the presence and properties of two enkephalin- 
degrading proteolytic activities which are present 
in the electric organ of Torpedo californica. 
2. MATERIALS AND METHODS 
A number of proteolytic activities from the 
brain have been implicated in the degradation of 
enkephalins. These include enkephalin degrading 
aminopeptidase, a neutral metalloendopeptidase 
termed ‘enkephalinase’ and angiotensin converting 
enzyme [3,10-121. However, no information is 
[Leu’]Enkephalin was supplied by Miles Yeda, 
Rehovot . Acetylcholine chloride, bestatin, 
puromycin dihydrochloride, phosphoramidon and 
catalase from bovine liver (twice crystallized) were 
purchased from Sigma St. Louis. Captopril (SQ 
14225) and the nonapeptide SQ 20881 were kindly 
provided by Squibb Institute for Medical 
Research, NJ. Thiorphan was kindly donated by 
Dr B.P. Roques, University Rene Descartes, Paris. 
Decamethonium was obtained from ICN-K and K, 
Plainview, NY. cr-[i2’I]Bungarotoxin (&BT) (20 
Ci/mmol) was prepared as in 1131. 
[tyro.syl-3,5-3H]Enkephalin (5-L-leucine) (20 
Ci/mmol) was obtained from Amersham Radio- 
chemical Centre and [acetyl-3H]acetylcholine 
iodide (90 mCi/mmol) from New England 
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Nuclear. T. californica electric organ was obtained 
in frozen form from Pacific Bio-marine, Venice, 
CA. 
2.1. Preparation of crude membranes 
Frozen electric organ (15 g) was homogenized 
(Sorvall Omni-Mixer 4 x 0.5 min, maximal speed) 
in 3 vols of 10 mM Tris-HCl containing 1 M NaCl 
(pH 7.4). The suspension was filtered through 
cheese-cloth and centrifuged at 1000 x g for 10 
min. The crude homogenate was centrifuged at 
30000 x g for 60 min, the supernatant (S~O) col- 
lected and the crude membrane pellet (PRO) dissolv- 
ed in 1.5 vols of 2 mM Tris-HCl (pH 7.4). In 
several experiments the crude homogenate was 
sedimented for 60 min at 100000 x g, the pellet 
dissolved in 10 mM Tris-HCl (pH 7.4) (Tris buf- 
fer) and resedimented under the same conditions 
(Pro0 membranes). Protein was determined as in 
1141. 
2.2. Sucrose gradient centrifugation 
For sucrose gradient centrifugation the PIOO 
membranes obtained from 25 g tissue were 
suspended in 5 ml Tris buffer containing 5% 
sucrose (w/w) and layered over 5 ml of 20% 
sucrose (w/w) on top of a continuous 26 ml 
29-40% (w/w) sucrose gradient. All sucrose solu- 
tions contained 10 mM Tris (pH 7.4). The gradient 
was centrifuged for 7 h at 80000 x g in an SW 27 
rotor at 5°C and 1 ml fractions were collected. 
2.3. Enzymatic assay 
Enzymatic hydrolysis of [Leu’lenkephalin was 
assayed essentially as in [ 151. Briefly, mixtures of 
labeled and unlabeled [Leu’lenkephalin (70 000 
cpm, 1 PM final concentration) were incubated 
with the enzyme for 30 min at 30°C in a final 
volume of 100~1 containing 10 mM Tris-HCl (pH 
7.4). Incubation was stopped by the addition of 
acetic acid (1 M final) and the hydrolysis products 
were separated from undegraded enkephalin either 
by filtration of the reaction mixtures through 
Porapak Q columns, to which enkephalin but not 
tyrosine, Tyr-Gly or Tyr-Gly-Gly were adsorbed 
[16], or by thin-layer chromatography (silica plates 
in ethyl acetate-isopropanol-acetic acid-water, 
40:40:1:19). Under the conditions tested, the 
hydrolysis of enkephalin did not exceed 30%. 
Acetylcholinesterase activity was assayed as in 
184 
[17]. Reaction mixtures (final volume 100 ~1) con- 
tained 3 mM acetylcholine (84000 cpm), 120 mM 
NaCl and 50 mM Tris-HCl (pH 7.4). The reaction 
was carried out for 10 min at room temperature. 
Binding of “‘I_(yBT was performed as follows: 
1251-labeled cvBT (8.5 nM, 30000 cpm) was in- 
cubated for 60 min at 30°C in a final volume of 
100 ~1 containing 120 mM NaCl, 100 fig BSA and 
50 mM Tris-HCl (pH 7.4). The reaction was ter- 
minated by filtration through EGWP cellulose 
acetate Millipore filters, as in [18]. Non-specific 
binding was determined in the presence of 0.1 mM 
decamethonium, and substracted from total 
binding. 
3. RESULTS AND DISCUSSION 
Homogenates of T. californica electric organ 
contain enzymes which degrade enkephalin. The 
thin-layer chromatography pattern of degradation 
of enkephalin by various subcellular fractions of 
the electric organ is shown in fig. 1. In the crude 
homogenate (panel A), the main proteolytic activi- 
ty is that of an aminopeptidase which cleaves the 
enkephalin at the Tyr’-GlJ peptide bond yielding 
free tyrosine. The second proteolytic activity is 
that of an endopeptidase cleaving the enkephalin 
at the Gly3-Phe4 peptide bond yielding Tyr-Gly- 
Gly. The aminopeptidase is a soluble enzyme and 
is responsible for 80% of the hydrolytic activity 
found in the Sso fraction (panel B). Only a residual 
aminopeptidase activity is associated with the 
crude membrane pellet (PRO, panel C). Further 
purification of the membranes, e.g. by means of 
sucrose gradient centrifugation, completely remov- 
ed the aminopeptidase. The endopeptidase activi- 
ty, on the other hand, was found in both the super- 
natant (30-40%) (panel B) as well as in the crude 
membrane fraction (60-70%) (panel 0. 
To characterize further the particulate endopep- 
tidase activity, we have purified the crude mem- 
branes by a sucrose density gradient. As seen in 
fig. 2, most of the proteolytic activity was 
associated with membranes and separated into 4-5 
peaks (panel A). A small part of the activity was 
soluble and migrated with a sedimention value 
lower than that of catalase (11.4 S). No major dif- 
ferences in the specificity of cleavage of the 
enkephalin molecules could be detected between 
the various peaks of the particulate and soluble en- 
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Fig. 1. Thin-layer chromatography of [Leu’lenkephalin degradation products following a 30 min incubation with: (A) 
5.6 pg crude homogenate (B). 3.6pg SSO, (C) 5.7 pg crude membranes (Pso). Protein samples were dialyzed against 10 
mM Tris buffer before assay. Markers were visualized by fluorescamine as in [la]. 
zyme (not shown). 
The sucrose density gradient described above 
separates heavy membrane fractions containing 
acetylcholine receptor from lighter membrane 
fractions containing acetylcholinesterase (panel B). 
Our results demonstrate that the endopeptidase 
does not comigrate exclusively with either of these 
membrane fractions, but rather migrates at various 
sucrose densities indicating that the endopeptidase 
activity is not directly associated with any specific 
membrane fraction. 
We have further characterized the two pro- 
teolytic activities by the use of selective inhibitors. 
The effect of a number of such inhibitors on the 
aminopeptidase is shown in table 1. Puromycin 
and bestatin are known to be very potent and selec- 
tive inhibitors of rat brain enkephalin degrading 
aminopeptidase [ 19,201. Puromycin (100 /IM) and 
bestatin (10 PM) inhibited almost completely the 
activity of the electric organ aminopeptidase (90 
and 86% inhibition respectively) and had no activi- 
ty (bestatin) or low inhibitory activity (puromycin) 
toward the soluble endopeptidase. Thiorphan (10 
pM), a potent inhibitor of the brain endopeptidase 
enkephalinase [21], did not affect the aminopep- 
tidase activity but completely inhibited the soluble 
endopeptidase (94% inhibition). Similar results 
were obtained with the membrane associated en- 
dopeptidase. This enzyme (fig.3) was completely 
inhibited by 10,~M thiorphan (panel B) but not af- 
fected by 10 PM bestatin (panel C). Based on the 
identical cleavage pattern and the inhibitory study, 
it seems that the soluble and particulate endopep- 
tidases are similar enzymes. 
Two endopeptidases, i.e., enkephalinase and 
angiotensin converting enzyme (ACE), have been 
implicated in the degradation of the Gly3-Phe? 
peptide bond of enkephalin [3,22]. Both enzymes 
are metalloenzymes but differ in their sensitivity to 
inhibition by various chelating compounds 
[23-261. To distinguish between these two activities 
in purified membranes of electric organ, we used 
the following selective inhibitors: thiorphan and 
phosphoramidon, potent inhibitors of the brain 
enkephalinase but weaker inhibitors of ACE 
[25,26], as well as captopril and SQ 20881, potent 
inhibitors of ACE and poor inhibitors of 
enkephalinase [3, 27-291. The results (table 2) 
185 
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Fraction Number 
Fig. 2. Sucrose density gradient of Torpedo electric 
organ membranes. AChE activity, cvBT specific binding 
and [Leu’lenkephalin hydrolysis were determined using 
0.1, 1 and 2.5 pl, respectively, from every fraction. The 
arrow indicates the position of catalase. AChE, 
acetylcholinesterase. 
Table 1 
The effect of various inhibitors on the hydrolysis of 
[Leu’lenkephalin by proteolytic activities present in SKI 
Inhibitor added 
Puromycin (100 ,uM) 
Bestatin (10 PM) 







*The enzymatic activity was determined by quantitative 
thin-layer chromatography of the reaction products 
show that relatively low concentrations (30 nM) of 
captopril or SQ 20881 inhibited the enzyme very 
effectively (85 and 52% inhibition, respectively). 
Thiorpan and phosphoramidon at the same con- 
centration were poor inhibitors (21 and > 1% in- 
hibition, respectively). At higher concentration (10 
,uM) phosphoramidon was still uneffective whereas 
thiorphan almost completely inhibited the enzyme 
(82% inhibition). This latter result agrees with the 
finding that thiorphan is more effective towards 
ACE than phosphoramidon [25,26]. Bestatin, 
which does not affect either of the endopeptidases 
mentioned above, did not inhibit the activity even 
at 10 ,uM. These results thus indicate that the en- 
dopeptidase present in Torpedo electric organ 
membrane resembles ACE. 
In summary, we have found two proteolytic ac- 
tivities in Torpedo electric organ that are capable 
of degrading [Leu’]enkephalin, a soluble 
aminopeptidase and a particulate endopeptidase. 
Based on the degradation pattern and inhibition 
studies, it seems that the aminopeptidase resembles 
the soluble aminopeptidase found in rat brain 
homogenates [ 18,191. The membrane-associated 
enzyme seems to resemble ACE and differs from 
the rat brain membrane-associated ndopeptidase 
enkephalinase. 
The significance of such an enzyme in what is 
considered to be a pure cholinergic synapse is still 
not known. Since enkephalins have been im- 
plicated in the modulation of neuromuscular 
Table 2 
The effect of various inhibitors on the hydrolysis of 
[Leu’lenkephalin by the endopeptidase present in wash- 
ed membranes* 
Inhibitor added Vo Inhibition at 
30 nM 10 pM 
Captopril 85 85 
SQ 20881 52 84 
Thiorphan 22 82 
Phosphoramidon 0 29 
Bestatin 3 6 
* Crude membranes (Pso) were resedimented at 30 000 x 
g for 60 min and further purified on a flotation sucrose 
gradient as in [30] [lo-54% sucrose (w/v) 12 h, 80000 
x g, SW 271. 3.4pg protein of the purified membranes 
were used per assay 
186 
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Fig. 3. Thin-Iayer chromatography of [Leu51enkephalin hydrolysed by 15.6pg crude membranes (PI& in the absence 
of inhibitors (A), in the presence of 10 ,uM thiorphan (B) and 10 pM bestatin (C). 
transmission, enzymes which degrade enkeph~ins 
could play an important role in the synaptic trans- 
mission in muscle as well as in electric organ. On 
the other hand, there is also a possibility that ACE 
participates in the cleavage of other neuropeptides 
(e.g. angiotensin I, bradykinin) and it is of interest 
to find out whether such modulatory neuropep- 
tides play a role in the function of the electric 
organ. 
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